

Ad hoc release

Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)

Biofrontera AG anticipates capital increase

Leverkusen, Germany, March 24, 2016 – The Management Board of Biofrontera AG (FSE: B8F) has today reached an agreement with institutional investors for a subscription of new shares of the company from a future capital increase from authorized capital (New Shares). A resolution for the capital increase is still to be made. The investors have committed to acquire up to 2,000,000 New Shares at an issue price of EUR 2.00 per New Share. Based on this agreement the Management Board of the company intends to resolve shortly on an increase of the registered capital of the company from authorized capital.

Shareholders of the company will be granted a subscription right for New Shares at the same issue price of EUR 2.00 per New Share. Altogether, the number of New Shares will be less than 2.5 million, such that the company will get additional liquidity of up to EUR 5 million.

Leverkusen, March 24, 2016

The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
e-mail: press@biofrontera.com